FDA OKs Guselkumab for Crohn’s Disease

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for moderately to severely active Crohn’s disease.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-oks-guselkumab-crohns-disease-2025a100070a?src=rss